Evaluation of Inflammatory Scores in Metastatic Colorectal Cancer Patients Undergoing Transarterial Radioembolization

Shamar Young; Ranjan Ragulojan; Soorya Todatry; Donna D'Souza; Jafar Golzarian; Siobhan Flanagan; Tina Sanghvi

doi:10.1007/s00270-022-03313-w

Evaluation of Inflammatory Scores in Metastatic Colorectal Cancer Patients Undergoing Transarterial Radioembolization

Cardiovasc Intervent Radiol. 2023 Feb;46(2):209-219. doi: 10.1007/s00270-022-03313-w. Epub 2022 Nov 23.

Authors

Shamar Young¹, Ranjan Ragulojan², Soorya Todatry², Donna D'Souza², Jafar Golzarian², Siobhan Flanagan², Tina Sanghvi³

Affiliations

¹ Department of Radiology, Division of Interventional Radiology, University of Arizona, 1501 N Campbell Ave, PO Box 245067, Tucson, AZ, 85724, USA. shamar@arizona.edu.
² Department of Radiology, Division of Interventional Radiology, University of Minnesota, 420 Delaware St SE, MMC 292, 55455, Minneapolis, USA.
³ Minneapolis VA Hospital, 1 Veterans Dr, Minneapolis, MN, 55417, USA.

PMID: 36416916
DOI: 10.1007/s00270-022-03313-w

Abstract

Purpose: To evaluate the correlation of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), aspartate aminotransferase-to-lymphocyte ratio (ALRI), systemic inflammation index (SII), and lymphocyte count to oncologic outcomes in metastatic colorectal cancer (mCRC) patients undergoing transarterial radioembolization (TARE).

Materials and methods: All patients undergoing TARE for mCRC were retrospectively reviewed at a single academic institution. A receiver operating characteristics (ROC) curve analysis was performed using a landmark survival point of 12 months, with an area under the curve (AUC) calculated. A cutoff point was determined by Youden's index and used to separate patients for OS and PFS analysis. Cox proportional-hazards models which included pertinent clinical factors were also created to evaluate PFS and OS.

Results: In total, 41 patients who underwent 66 TARE treatments were included. A correlation was seen between post-treatment ALRI < 45 (HR: 0.38 (95%CI: 0.17-0.86), p = 0.02) and PFS. Patients with a pretreatment ALRI score < 20 had a significantly longer OS (HR: 0.49 (95%CI: 0.19-0.88), p = 0.02) as did those with a post-treatment lymphocyte count > 1.1 10⁹/L (HR: 0.27 (95%CI: 0.11-0.68), p = 0.005). In multivariate analysis of PFS, post-treatment lymphocyte count (HR: 8.46 (95%CI: 1.14-62.89), p = 0.044) was the only significantly associated inflammatory marker and presence of extrahepatic disease (HR:8.46 (95%CI: 1.14-62.89, p = 0.044) also correlated. Multivariate analysis of OS showed that pretreatment PLR (HR:1.01 (95%CI:1.-1.03), p = 0.02) and post-treatment NLR (HR:0.33 (95%CI:0.14-0.76), p = 0.009), PLR (HR:0.98 (95%CI:0.97-1), p = 0.046), SII (HR:1.04 (95%CI:1.01-1.08), p = 0.014), and lymphocyte count (HR:0.07 (95%CI:0.01-0.16), p = 0.003) were significantly associated.

Conclusion: Inflammatory markers may be associated with OS and PFS in mCRC patients undergoing TARE.

Keywords: Colorectal cancer; Inflammatory markers; Transarterial radioembolization.

MeSH terms

Colonic Neoplasms*
Humans
Lymphocyte Count
Lymphocytes
Neutrophils
Prognosis
Rectal Neoplasms*
Retrospective Studies